CSL Aktie

CSL Rule of 40

Delisted·19. jun. 2026

Rule of 40 for CSL (CSL.AX) pr. 25. aug. 2026 er 31,50 %. I foregående år var Rule of 40 36,95 % — en ændring på -14,75 % (lavere).

Rule of 40

31,50 %

YoY

-14,75%

Senest opdateret:

Rule of 40 for CSL er 2026 31,50 % . Rule of 40 for CSL var 2025 36,95 % . Det falder dermed med -14,75% lavere sammenlignet med året før.

CSL Rule of 40 historik

  • 3 år

  • 10 år

  • 25 år

  • Maks

Rule of 40
Date
Rule of 40
1. jan. 2018
44,41 USD
1. jan. 2019
37,20 USD
1. jan. 2020
36,86 USD
1. jan. 2021
43,03 USD
1. jan. 2022
30,16 USD
1. jan. 2023
50,46 USD
1. jan. 2024
36,95 USD
1. jan. 2025
31,50 USD
CSL Rule of 40 historik
ÅRRule of 40YoY
31,50 %-14,75%
36,95 %-26,77%
50,46 %+67,31%
30,16 %-29,90%
43,03 %+16,74%
36,86 %-0,92%
37,20 %-16,23%
44,41 %+14,58%
38,76 %+20,49%
32,17 %-3,67%
33,39 %
Access this data via the Eulerpool API

CSL Aktieanalyse

Hvad laver CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om CSL aktie

Rule of 40 for CSL er 31,50 % i 2026.

På Eulerpool kan du finde den fuldstændige historiske udvikling af Rule of 40 CSL siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

Rule of 40 siger, at en virksomheds omsætningsvækstrate plus fortjenstmargin skal overstige 40%. Det bruges bredt til at vurdere SaaS- og højtvækstvirksomheder.

Access this data via the Eulerpool API

Kvalitet — CSL

Alle nøgletal — CSL